T he National Institute for Clinical Excellence (NICE) has recommended that implantable cardioverter defibrillators should be routinely considered for patients who have survived ventricular fibrillation or ventricular tachycardia with haemodynamic compromise for secondary prevention of arrhythmic death. It also recommends it in certain patients who have not yet had a serious arrhythmic event but who are at high risk of sudden cardiac death as primary prevention. This second group comprises mainly patients who have survived a myocardial infarction. Only a tiny minority of these patients is currently being investigated and treated with implantable defibrillators.
After an infarction, impaired ventricular function with an ejection fraction of 35% or less, non-sustained ventricular tachycardia (three beats or more) on ambulatory 24 hour monitoring, and inducible ventricular tachycardia at electrophysiological testing identify a subgroup of patients at high risk of sudden death. Paradoxically, antiarrhythmic drugs increase the risk of death and should be avoided in patients with significantly impaired ventricular function.
1 At best, amiodarone decreases the risk of sudden death slightly but does not affect overall mortality, with a risk reduction of 13%-15%.
2
Two prospective randomised controlled trials of preventive strategies have shown the benefit of the implantable cardioverter defibrillator in this high risk group. The multicentre automatic defibrillator trial, or MADIT, compared the implantable cardioverter defibrillator with best medical treatment, which included amiodarone in 74% of the control group.
3 It was a relatively small study, justified by its sequential trial design. The multicentre unsustained tachycardia trial, or MUSTT, compared an electrophysiologically guided strategy with no antiarrhythmic therapy. 4 The strategy involved serial drug testing-antiarrhythmic drugs were given, and the electrophysiology study repeated to determine if ventricular tachycardia could still be induced. Suppression of induction of ventricular tachycardia was deemed a success. If not, antiarrhythmic drugs were withdrawn and an implantable cardioverter defibrillator implanted. Although this was not a trial of the implantable cardioverter defibrillator itself, benefit was seen only in those patients treated with defibrillators.
Both these trials have shown that implantable cardioverter defibrillators confer a relative risk reduction of 54%-60% in all-cause mortality. Using this evidence the American College of Cardiology, American Heart Association, 5 National Institute for Clinical Excellence, 6 and European Society of Cardiology 7 have all recommended using an implantable cardioverter defibrillator as a primary prevention strategy in such high risk patients. In addition, NICE recommends that screening programmes should be put in place so that these patients can be identified.
Screening requires assessment of ventricular function, 24 hour ambulatory monitoring in those with an ejection fraction of less than 35%, and an electrophysiological study in those with non-sustained ventricular tachycardia aimed at provoking sustained ventricular tachycardia. Despite the recommendation in September 2000 that screening programmes be put in place, there seems to be none in the United Kingdom. Screening should be undertaken as a cascade as identification requires all three criteria. Assessment of ventricular function is already required by the national service framework for heart disease, for which extra resource should be available, but only a minority of post-infarction patients undergo ambulatory monitoring and extremely few undergo electrophysiological studies.
Best guesses suggest that after an infarction about 1% of patients will fulfil all three criteria and therefore be considered for cardioverter defibrillator implantation. [8] [9] [10] [11] These estimates are based on a variety of assumptions-that 4%-16% of post-infarction patients will have an ejection fraction of 35% or less, 8 10 11 of these 12%-16% will have non-sustained ventricular tachycardia on ambulatory monitoring, 8 10 and that sustained ventricular tachycardia will be inducible at electrophysiological study in 22%-35% of these.
11 12 There are 300 000 myocardial infarctions each year in the United Kingdom; over half the patients survive. Using these assumptions, over 1500 patients each year should be considered for an implantable cardioverter defibrillator as a primary prevention strategy. If the recommendations made by NICE are adopted many patients should be screened after infarction. About 24 000 should undergo ambulatory monitoring; 16%, or about 4000, should undergo electrophysiological study, and 1%, or about 250, should have a cardioverter defibrillator implanted.
Since the guidance from NICE was published, a further primary prevention trial (MADIT 2) has shown a relative reduction in mortality of 31% in postinfarction patients treated with an implantable cardioverter defibrillator compared with the control group receiving usual treatment.
13 This trial used a much simplified selection criterion-ejection fraction less than 30% after myocardial infarction-obviating the need for the screening cascade described by NICE. It does suggest, however, that at least five times as many patients as fulfil the current NICE criteria might benefit from an implanted defibrillator.
Increasing the number of patients being investigated and treated according to the guidance from NICE will need much additional resource. Till then few British patients will receive the care recommended by NICE and widely available in the Western world. 
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Bisphosphonates as adjuvant treatment for breast cancer
Their effects are unclear, and long term trials are needed B isphosphonates are potent inhibitors of the osteoclastic bone resorption that is associated with skeletal metastases, with proved efficacy in reducing skeletal complications in metastatic cancer. Randomised clinical trials investigating the adjuvant use of bisphosphonates to prevent bone metastases in patients with breast cancer have yielded intriguing yet conflicting results. Defining the potential role of these agents in the treatment of breast cancer is of great clinical relevance.
The skeleton is the first site of recurrence in 25-40% of patients with metastatic breast cancer. The development of bone metastases entails complex interactions between cancer cells and the microenvironment of bones. In the early establishment of metastases, bone is destroyed by the osteoclast, which is activated by a variety of cytokines produced directly or indirectly by the tumour cell. As bone matrix is broken down, a rich supply of mitogenic factors is released, which in turn can lead to increased proliferation of cancer cells.
Bisphosphonates are effective in treating conditions in which excessive bone resorption and osteoclast activity prevail, including osteoporosis and Paget's disease of bone. Several randomised clinical trials in patients with breast cancer with bone metastases have shown the ability of bisphosphonates to reduce skeletal related events and symptoms, including pathological fractures, surgery, radiation, compression of the spinal cord, hypercalcaemia, and pain, although they have not shown improved survival.
1-6 Clodronate and pamidronate have been evaluated extensively in patients with metastatic cancer and are widely used in oncology.
1-3 Zoledronic acid and ibandronic acid represent highly potent, newer generation bisphosphonates with recently shown benefit in reducing skeletal related events. [4] [5] [6] Preclinical studies show that bisphosphonates might also be capable of preventing the development of bone metastases. Laboratory data show that bisphosphonates can inhibit adherence of breast cancer cells to the bone matrix, inhibit release of growth factors stored in the bone matrix, and enhance the sensitivity of osteoclasts, macrophages, and tumour cells to apoptosis.
Three randomised clinical trials of the oral bisphosphonate clodronate as adjuvant treatment in breast cancer have yielded conflicting results. A German trial of 302 patients with primary breast cancer with immunocytochemical evidence of cancer cells in a bone marrow aspirate randomised patients to two years of clodronate or control. At almost five years of follow up, a reduction in the recurrence of bone metastases, a trend towards reduction in visceral metastases, and an increase in overall survival were seen in the clodronate group. 7 8 The effect of clodronate as an adjuvant seemed weakened with longer follow up.
A Finnish trial including 299 women with lymph node positive breast cancer randomised to three years of clodronate as an adjuvant showed virtually the opposite result, with no effect on the rate of bone metastasis and a deleterious effect on relapse rates of non-bone metastasis as well as survival. 9 After five years of follow up, bone metastases were detected equally in the clodronate and placebo groups, and non-skeletal metastases were significantly more common in the clodronate group. Overall survival was significantly worse in the clodronate group.
